Galaxy Biomedical Investment Co Ltd operates in the Transformers, except electronic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Galaxy Biomedical Investment Co Ltd with three other
companies in this sector in China:
San Bian Science& Technology Co Ltd
(2018
sales of 570.67 million Chinese Renmimbi [US$80.82 million]
of which 62%
was Oil-immersed transformer),
Ceepower Co Ltd
(995.64 million Chinese Renmimbi [US$141.00 million]
of which 76%
was Grid intelligent business), and
Changshu Ruite Electric Co Ltd
(488.81 million Chinese Renmimbi [US$69.22 million]
of which 56%
was Ship cabin automation system).
Sales Analysis.
Galaxy Biomedical Investment Co Ltd reported sales of 759.36 million Chinese Renmimbi (US$107.54 million)
for the
year ending
December of 2018.
This
represents
a
sharp
decrease of 27.4%
versus 2017, when the company's sales were 1.05 billion Chinese Renmimbi.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Galaxy Biomedical Investment Co Ltd had sales
of 784.01 million Chinese Renmimbi.
Contributing to the drop in overall sales was the 48.7% decline
in Transmission and Control Equipment Manuf, from 687.57 million Chinese Renmimbi to 352.49 million Chinese Renmimbi.
There were also decreases in sales in
It Network and Services (down 4.5% to 51.50 million Chinese Renmimbi)
and
Pharmaceuticals (down 21.8% to 15.73 million Chinese Renmimbi)
.
However, these declines were partially offset by the increase in sales of
Electrical Components and Parts (up 7.6% to 209.79 million Chinese Renmimbi)
and
Technology Services (up 90.8% to 65.47 million Chinese Renmimbi)
.